Technologies

The dramatic global health emergency due to the SARS-CoV-2 pandemic requires new diagnostic devices capable of identifying the presence of virus particles in patient biological samples. In this direction, the development of an innovative low-cost test, which provides the result within a few minutes, which is reproducible and which can reveal the direct presence of even a few viral particles, would be of fundamental importance for the monitoring and containment of the pandemic.

Inert biomedical devices with modular load-bearing function designed with peculiar multi-domain composite microstructures. The reference compositional system is Zirconia-Alumina with a prevailing overall composition of customizable zirconia or alumina. Examples of devices are 3D structures consisting of parts with differentiated functional properties, due to different composition/microstructure/architecture, and further functionalizable ex-post to favor and improve the stabilization of the implantation by newly formed bone in superior quantity and quality.

22q11.2DS(DGS) deletion syndrome is a rare and phenotypically variable multiorgan syndrome, currently without any cure. Our aim is to develop a standardized approach to formulate pharmacological products useful for clinical trials direct to prevent some serious clinical manifestations of adolescence and adulthood, such as neuropsychiatric and musculoskeletal diseases, or to eliminate or improve cardiovascular defects during embryonic development.

NIRS is a non-invasive technique for the human brain cortex imaging based on the measurement of the NIR light emitted by suitable optical sources placed on the patient head and backdiffused to the surface after passing through the brain tissues. NIRS monitors the percentage of oxygenated and reduced hemoglobin  in the blood, and it allows the real time functional imaging of the brain cortex also in tomographic mode (Diffuse Optical Tomography - DOT).

Detection devices for the presence of molecules of interest (analytes) enjoyed a renewed burst with the introduction of biological components (biosensors). Their high specificity is often used in various fields, from environmental monitoring and biomedicine to the protection and promotion of agri-food products. However, the high cost of production and the lack of compatibility with mass sampling (high-throughput) sometimes limit their use.

We have identified the presence of the poorly characterized precursor proNGF-A in human tissues, deposited its coding nucleotide sequence (GenBank MH358394) and demonstrated its neuroprotective and neurotrophic activity in vitro and in vivo. We inserted mutations into the native molecule, identified through computational analysis, which allow proNGF-A production by eukaryotic expression systems, through a method currently validated on a laboratory scale.

We have identified compounds that show a neuroprotective action in vivo, in models of neurodegenerative diseases (e.g. SMA, Parkinson, Alzheimer, Huntington) in the model organism C. elegans. These compounds consist of: mixtures of 22 natural extracts, 15 natural molecules and 11 synthetic molecules.

Safe, efficient and specific nano-delivery systems are increasingly needed for precision and regenerative medicine and targeted therapies (e.g. anticancer and antimicrobial therapies), as well as for  the cosmetic and nutraceutical sectors’ applications. Despite the appreciable success of synthetic nanovectors, like for example liposomes, their clinical and market application is hampered by some limitations: • large scale production, • low cost production • intrinsic toxicity • limited cellular uptake • limited consumer acceptance.